Langlois is proud to have advised its client, the LSL Pharma Group, a publicly traded integrated Canadian pharmaceutical company listed on the TSX Venture Exchange, on its most recent series of combined financings.
The transaction was completed through a non-brokered private placement of units and the settlements of debts in units. Langlois ably managed the closings of these financings and the approval filings required by the TSX Venture Exchange. Initially announced at C$8 million, the total amount of the financings increased to C$10,228,758 upon the closing of the second and final tranche of the financing.
This series of transactions exemplifies Langlois’ expertise in the capital market segment, as well as the confidence placed in us by our clients. Those responsible for this successful closing include Éric Archambault, Pierre-Hubert Séguin, François-Alexandre Marois, Juliane Simon and Sylvain Aird.
About LSL Pharma Group
The LSL Group is a Canadian integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.